临床肿瘤学次世代定序仪市场规模、份额和成长分析：按技术、工作流程、应用、最终用途和地区 - 2025-2032 年行业预测

2023年临床肿瘤次世代定序仪的全球市场规模估值为3.8亿美元，从2024年的4.4042亿美元成长到2032年的14.3395亿美元，在预测期内（2025年）预计复合年增长率为15.9%从2013 年到2032 年）。

次世代定序(NGS) 为全面的基因组分析提供可扩展的高通量解决方案，正在彻底改变临床肿瘤学。这种先进的定序技术能够识别罕见癌症和新型癌症突变，有助于检测家庭遗传性癌症风险，并帮助为个别患者选择标靶治疗。 NGS 过程的关键是 DNA 预测定序，它执行样品製备以获得准确的定序结果。我们的平台透过分析原始资料对基因组变化进行分类并解释与现有实验和核准治疗的相关性，增强了 NGS 的临床效用。因此，NGS资料处理系统的整合对于提供个人化肿瘤治疗并帮助医疗保健专业人员根据基因组见解做出明智的治疗决策将变得越来越重要。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 案例研究分析

临床肿瘤学次世代定序仪市场规模：依技术分类

• 市场概况
• 全基因组序列分析
• 全EXOME定序
• 标靶定序和定序

临床肿瘤学次世代定序仪市场规模：依工作流程

• 市场概况
• NGS预测序
• NGS定序
• NGS资料分析

临床肿瘤学次世代定序仪市场规模：按应用分类

• 市场概况
• 筛检
• 散发性癌症
• 遗传性癌症
• 伴同性诊断
• 其他诊断

临床肿瘤学次世代定序仪市场规模：依最终用途分类

• 市场概况
• 医院
• 诊所
• 研究所

临床肿瘤学次世代定序仪的市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• Illumina, Inc.（US）
• Thermo Fisher Scientific, Inc.（US）
• F. Hoffmann-La Roche AG（Switzerland）
• Qiagen NV（Netherlands）
• Agilent Technologies, Inc.（US）
• BGI Genomics Co., Ltd.（China）
• PerkinElmer, Inc.（US）
• Oxford Nanopore Technologies, Inc.（UK）
• Pacific Biosciences of California, Inc.（US）
• Eurofins Scientific SE（Luxembourg）
• Myriad Genetics, Inc.（US）
• Guardant Health, Inc.（US）
• Natera, Inc.（US）
• Biocartis Group NV（Belgium）

结论和建议

Global Clinical Oncology Next Generation Sequencing Market size was valued at USD 380.0 million in 2023 and is poised to grow from USD 440.42 million in 2024 to USD 1433.95 million by 2032, growing at a CAGR of 15.9% during the forecast period (2025-2032).

Next Generation Sequencing (NGS) is revolutionizing clinical oncology by offering scalable, high-throughput solutions for comprehensive genomic analysis. This advanced sequencing technology enables the identification of rare and novel cancer mutations, facilitates the detection of hereditary cancer risk among family members, and informs the selection of targeted therapies tailored to individual patients. Key to the NGS process is DNA pre-sequencing, which prepares samples for accurate sequencing outcomes. Our platform enhances the clinical utility of NGS by analyzing raw data to categorize and interpret genomic alterations in correlation with existing experimental and approved treatments. Consequently, the integration of NGS data processing systems is increasingly vital for delivering personalized oncology care, empowering healthcare professionals to make informed treatment decisions based on genomic insights.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Clinical Oncology Next Generation Sequencing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Clinical Oncology Next Generation Sequencing Market Segmental Analysis

Global Clinical Oncology Next Generation Sequencing Market is segmented by Technology, Workflow, Application, End-use and region. Based on Technology, the market is segmented into Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing. Based on Workflow, the market is segmented into NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis. Based on Application, the market is segmented into Screening, Sporadic Cancer, Inherited Cancer, Companion Diagnostics and Other Diagnostics. Based on End-use, the market is segmented into Hospitals, Clinics and Laboratories. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Clinical Oncology Next Generation Sequencing Market

The Global Clinical Oncology Next Generation Sequencing (NGS) market is experiencing significant growth driven by advancements in research and technology. The rising demand for NGS technologies aligns with the growing emphasis on personalized medicine and companion diagnostics. Additionally, the expansion of NGS applications in liquid biopsy-specifically for sequencing circulating tumor DNA-promises to enhance revenue generation in the sector by facilitating non-invasive cancer profiling and real-time monitoring. Furthermore, increased funding for oncology research is contributing to the market's expansion, as innovative research programs and technological advancements continue to propel the utilization of NGS in clinical oncology settings.

Restraints in the Global Clinical Oncology Next Generation Sequencing Market

The Global Clinical Oncology Next Generation Sequencing market faces significant constraints primarily due to the high costs involved. Patients worldwide struggle with the exorbitant expenses associated with this advanced clinical oncology process, creating substantial barriers to access. Ongoing economic challenges and political instability in various countries raise doubts about the sustainability of public healthcare funding. Furthermore, the lack of effective and affordable cancer treatments negatively affects population health, particularly in low-income nations, leading to decreased life expectancy. The high costs of consumables and specialized equipment for treating rare cancers further exacerbate the situation, stifling market growth and limiting accessibility.

Market Trends of the Global Clinical Oncology Next Generation Sequencing Market

The Global Clinical Oncology Next Generation Sequencing (NGS) market is poised for significant growth driven by the rising adoption of NGS in liquid biopsies, which enable the non-invasive sequencing of circulating tumor DNA. This technology allows for efficient tumor profiling and real-time cancer surveillance, addressing the urgent need for innovative diagnostic solutions. The advanced capabilities of NGS have evolved to facilitate simultaneous sequencing of multiple genomes, enhancing its appeal among laboratories for routine diagnostics. Factors such as accelerated processing speed, increased sensitivity, and reduced cost per sample are further propelling the market as providers leverage NGS to advance cancer research and patient care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Study Analysis

Global Clinical Oncology Next Generation Sequencing Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing

Global Clinical Oncology Next Generation Sequencing Market Size by Workflow & CAGR (2025-2032)

• Market Overview
• NGS Pre-Sequencing
• NGS Sequencing
• NGS Data Analysis

Global Clinical Oncology Next Generation Sequencing Market Size by Application & CAGR (2025-2032)

• Market Overview
• Screening
• Sporadic Cancer
• Inherited Cancer
• Companion Diagnostics
• Other Diagnostics

Global Clinical Oncology Next Generation Sequencing Market Size by End-use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Laboratories

Global Clinical Oncology Next Generation Sequencing Market Size & CAGR (2025-2032)

• North America (Technology, Workflow, Application, End-use)
  • US
  • Canada
• Europe (Technology, Workflow, Application, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Technology, Workflow, Application, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Technology, Workflow, Application, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Technology, Workflow, Application, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Illumina, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BGI Genomics Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Nanopore Technologies, Inc. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacific Biosciences of California, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific SE (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocartis Group NV (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations